Dr. Ruben Lopez: RNA Therapy Formulation at Any Scale | Stories in Life Sciences

RNA therapy formulation is one of the most resource-intensive steps in preclinical development. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Ruben Lopez, Ph.D., Founder of Nanofacile, to explore how his Montreal-based biotech is changing how researchers and biotech companies approach LNP formulation.Ruben holds a Ph.D. from École de technologie supérieure and brings a background in mechatronics, microfluidics, and cancer biology to the problem of RNA delivery. Nanofacile is developing tools that let scientists formulate RNA-loaded lipid nanoparticles faster, at lower cost, and without requiring specialized formulation expertise. The insights behind the platform came from 140+ customer interviews that revealed the real barriers researchers face in this space.We cover:How RNA therapy formulation works and why it creates a bottleneck in preclinical developmentWhat Nanofacile Symphony does and how it works in any wet lab with a centrifugeHow the AI formulation companion reduces iteration cycles in LNP developmentWhat 140+ customer interviews revealed about the real barriers in RNA formulationBuilding a team organically from shared labs and incubators in MontrealThe Montreal biotech ecosystem: District 3, Centech, the Merck Digital Science Studio, and CQDMWhat the First Access program is and how researchers can get early access to Nanofacile SymphonyWho this is for: biotech founders and researchers working on RNA therapies, LNP formulation, targeted drug delivery, or anyone navigating the preclinical development process with limited resources.Guest: Ruben Lopez, Ph.D.Founder, Nanofacile https://www.nanofacile.bio https://ca.linkedin.com/in/ruben-lopez-nanofacile https://ca.linkedin.com/company/nanofacileHost:Christopher WilsonFounder, MedAxis AIwww.medaxisai.org https://www.linkedin.com/in/christopher-wilson-medaxisaihttps://www.linkedin.com/company/medaxisai